Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Immunotherapy Année : 2021

Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database

Résumé

Aim: To describe real-world pembrolizumab administration and outcomes for advanced melanoma in France. Materials & methods: Using the MelBase longitudinal database, this multicenter historical-prospective study examined treatment and outcomes of patients with nonuveal, unresectable stage III/IV melanoma initiating pembrolizumab from April 2016 to September 2017, with follow-up to September 2019. Kaplan–Meier time-to-event analyses were conducted. Results: Of 223 patients (median age 67; 51% men), 134 (60%), 36 (16%) and 53 (24%) initiated pembrolizumab in first-, second- and third-line, respectively. Median overall survival (months) was 32.6 (95% CI: 20.3–not reached [NR]), 14.4 (8.6–NR) and 9.3 (6.4–NR), respectively. Best real-world tumor response of complete or partial response was recorded for 49, 39 and 26% of patients, respectively. Conclusion: Study results support benefits of pembrolizumab therapy for advanced melanoma.
Fichier principal
Vignette du fichier
10.2217-imt-2021-0077.pdf (1.01 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03713274 , version 1 (04-07-2022)

Identifiants

Citer

Emilie Casarotto, Sheenu Chandwani, Laurent Mortier, Olivier Dereure, Caroline Dutriaux, et al.. Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database. Immunotherapy, 2021, 13 (11), pp.905-916. ⟨10.2217/imt-2021-0077⟩. ⟨hal-03713274⟩
33 Consultations
41 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More